levprot

What levprot does

Levprot Bioscience (LEVPROT BIOSCIENCE, S.L.U.) is a privately held Spanish biotechnology company founded in 2018 and headquartered in Zaragoza, operating from ISO 9001 and ISO 13485 certified facilities spanning more than 5,000 sqm. The company specializes in yeast-based precision fermentation for the development and industrial-scale production of recombinant proteins, operating through a proprietary end-to-end platform branded YEASTech® that covers genetic design, strain engineering, lab-scale optimization, pilot-scale process development, industrial fermentation, downstream processing, protein characterization, and regulatory compliance support. The platform is segmented into three sub-brands — YEASTprot (recombinant proteins for nutraceutical/foodtech/cell culture), YEASTzyme (precision-fermented enzymes for diagnostics, industry, and research), and YEASTmAb (yeast-derived monoclonal antibodies for IVD) — and underpins a catalog that includes multiple grades of recombinant bovine serum albumin (Diagnostic, Molecular Biology, Pharma, NutraGrade, Cell Culture), the Brazzein sweet protein, and a range of PCR/RT enzymes and reagents such as Taq DNA Polymerase, M-MLV Reverse Transcriptase, MasterYeast® qPCR Master Mix, Thermolabile dsDNase I, DNase I, Proteinase K, and Inorganic Pyrophosphatase 1. Target customers are B2B and span in vitro diagnostics manufacturers, molecular biology laboratories, cell culture and bioprocessing firms (including cultivated meat), and next-generation nutraceutical and foodtech companies.

The company monetizes through a direct-sales, B2B CDMO/CMO model organized around four revenue streams: Contract Manufacturing Organization (CMO) for certified pilot-to-industrial-scale production, Contract Development Organization (CDO) for end-to-end development projects, Core Reagent Solutions (CRS) for catalog sales of high-purity enzymes and recombinant proteins, and Cooperative Project Organization (CPO) for co-development partnerships in Life Sciences, Cell Culture, and Nutraceuticals. All sales are quote-based with no public pricing, and the go-to-market is anchored on heavy trade fair participation across Europe (MEDICA, BIOSPAIN, PEGS Europe, Food4Future), the Middle East (MEDLAB, WHX Labs Dubai), the US (ADLM Chicago), and Asia (BIOJAPAN, AFTEA Singapore), supported by Spain's ICEX export promotion program. Growth has been financed almost entirely through non-dilutive Spanish government grants (CDTI, Government of Aragon, Ministry of Science and Innovation) across collaborative projects in mRNA vaccines, NGS-based personalized medicine, lipid nanoparticle nucleic acid therapies, and healthy bakery products, with cumulative grant funding exceeding €2 million across 2021–2025. The company has not raised institutional equity and operates without a disclosed parent entity, leaving ownership and capitalization structure opaque to outside observers.

Name

levprot

Legal name

LEVPROT BIOSCIENCE, S.L.U.

Website

https://levprot.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Levprot Bioscience is a Spanish biotechnology company that develops and manufactures recombinant proteins via proprietary yeast-based precision fermentation, supplying catalog reagents, enzymes, and CDMO services to IVD manufacturers, cell culture and bioprocessing firms, and foodtech and nutraceutical companies.

Ownership category

akta.pro rank

Product category

Biotechnology CDMO Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)

akta.pro primary industry

Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

akta.pro secondary industries

Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Cultures, Probiotics & Fermentation Ingredients (Starter Cultures, Yeast, Adjuncts) (CRADAOAI)

Keywords

• Recombinant protein production
• Precision fermentation services
• Biotech CDMO manufacturing
• Yeast expression platform
• Life sciences raw materials

Headquarters

HQ city

Calatayud

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Operations, Personnel, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Organization (CMO): Certified, scalable production of recombinant biomolecules tailored to industrial needs from pilot batches to full-scale manufacturing. Revenue generated through project-based manufacturing contracts with biotech, diagnostics, and foodtech companies.
2. Contract Development Organization (CDO): End-to-end development services from genetic design to process optimization and scale-up. Billed through project milestones or fixed-price development contracts.
3. Core Reagent Solutions (CRS): Supply of high-purity enzymes and recombinant proteins as essential raw materials for advanced research and diagnostics. Revenue through product catalog sales of recombinant proteins, enzymes, and antigens.
4. Cooperative Project Organization (CPO): Co-development partnerships with biotech teams for strategic high-impact solutions. Revenue through collaborative R&D project agreements in Life Sciences, Cell Culture, and Nutraceuticals.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Levprot Bioscience develops and manufactures yeast-expressed recombinant proteins and enzymes via its proprietary YEASTech® precision fermentation platform. It supplies high-purity, animal-free reagents (rBSA in multiple grades, PCR/RT enzymes, antigens) for in-vitro diagnostics, molecular biology, cell culture, and nutraceutical applications, and provides contract development and manufacturing (CDMO/CDO/CPO) services from gene design to industrial-scale production.

Product overview

Levprot Bioscience is a European biotechnology company offering a comprehensive portfolio of yeast-expressed recombinant proteins and precision fermentation services. The core offering centers on the proprietary YEASTech® Platform, which encompasses three sub-brands: YEASTprot (recombinant proteins for nutraceuticals and foodtech), YEASTzyme (precision-fermented enzymes for diagnostics and research), and YEASTmAb (yeast-derived monoclonal antibodies for IVD). The product portfolio spans multiple grades of Recombinant Bovine Serum Albumin (rBSA) for diagnostics, molecular biology, pharma, and nutraceuticals; Brazzein sweet protein; PCR/RT enzymes including Taq DNA Polymerase, M-MLV Reverse Transcriptase, and MasterYeast® qPCR Master Mix; essential reagents such as thermolabile dsDNase I, DNase I, Proteinase K, and Inorganic Pyrophosphatase 1; Giardia intestinalis CWP1 antigens; and cell culture supplements. The company also provides CMO/CDMO services for custom recombinant protein development and manufacturing.

Differentiator

Problem solved

Functional benefit

Brands

• YEASTech®: Proprietary yeast-based recombinant protein expression platform encompassing services for recombinant proteins (YEASTprot), enzymes (YEASTzyme), and monoclonal antibodies (YEASTmAb) for life sciences, cell culture, and nutraceuticals.
• MasterYeast®

Products and services

• YEASTech® Platform (CDMO/CDO/CPO/CRS) Proprietary end-to-end yeast-based recombinant protein expression platform offering gene design, strain engineering, lab-to-industrial scale fermentation, downstream processing, characterization, lyophilization/spray-drying, and regulatory compliance support for biotech, diagnostics, foodtech, and nutraceutical clients.
• rBSA (Recombinant Bovine Serum Albumin) – Diagnostic Grade Animal-free recombinant albumin produced via yeast-based precision fermentation for IVD manufacturers and diagnostic laboratories requiring batch consistency, regulatory compliance, and elimination of TSE/BSE contamination risks.
• rBSA (Recombinant Bovine Serum Albumin) – Molecular Biology Grade High-purity recombinant BSA for molecular biology workflows including PCR, qPCR, RT-PCR, enzyme stabilization, and nucleic acid manipulation where reproducibility and accuracy are essential.
• rBSA (Recombinant Bovine Serum Albumin) – Pharma Grade Recombinant albumin for pharmaceutical R&D and bioprocess development, designed for process development, analytical development, and bioprocess scale-up studies in pharma and biopharma applications.
• rBSA (Recombinant Bovine Serum Albumin) – NutraGrade Animal-free recombinant albumin for nutraceutical formulations, offering complete amino acid profile, antioxidant potential, and bioactive stability for sports nutrition, healthy aging, and immune support applications.
• Brazzein – The Sweet Protein Clean-label sweet protein produced via precision fermentation in yeast, approximately 1,600 times sweeter than sugar with zero calories and glycemic impact, featuring antioxidant and anti-inflammatory properties for food and nutraceutical applications.
• Taq DNA Polymerase Thermostable DNA polymerase produced in a recombinant yeast system, catalyzing 5'→3' DNA synthesis for routine PCR amplification, DNA labeling, and qPCR applications in molecular biology and diagnostics labs.
• M-MLV Reverse Transcriptase Reverse transcriptase enzyme for generating first-strand cDNA from mRNA, total RNA, or viral RNA for RT-(q)PCR and cDNA cloning applications in molecular biology research and diagnostics.
• qPCR Master Mix (MasterYeast®) for DNA samples 2X concentrated Hot Start qPCR Master Mix optimized for DNA amplification in conventional PCR and real-time PCR, containing Hot Start Taq DNA polymerase, dNTPs, and optimized buffer.
• Thermolabile dsDNase I Endonuclease with strong preference for double-stranded DNA that can be easily inactivated by heat treatment at 55°C, used to specifically degrade dsDNA while leaving ssDNA and RNA intact in molecular biology workflows.
• DNase I from Bos taurus Recombinant endonuclease that non-specifically cleaves DNA to release di-, tri-, and oligonucleotide products with 5'-phosphorylated and 3'-hydroxylated ends, acting on ssDNA, dsDNA, chromatin, and RNA:DNA hybrids.
• Proteinase K – Molecular Biology Grade Broad-spectrum serine protease from Tritirachium album that efficiently digests proteins by cleaving peptide bonds adjacent to aromatic and aliphatic amino acids, suitable for removing DNases and RNases during nucleic acid purification.
• Inorganic Pyrophosphatase 1 Metalloprotease enzyme that catalyzes hydrolysis of inorganic pyrophosphate to two orthophosphates, requiring Mg2+ for maximal activity, used for high-yield RNA synthesis by in vitro transcription.
• Giardia intestinalis CWP1 Antigen Giardia intestinalis cyst wall protein 1 expressed and purified from Pichia pastoris, a principal target for monoclonal antibodies in clinical specimens for diagnosis of giardiasis, available in monomeric and trimeric formats.
• Cell Culture Supplements Animal-free recombinant proteins and growth factors for cell culture media applications, designed to replace animal-derived components like FBS with safer, scalable, and defined solutions for biopharmaceutical manufacturing, cultivated meat, and advanced biotech research.
• Next-Generation Sequencing (NGS) Services Next-Generation Sequencing services including whole genome sequencing (WGS), de novo genome assembly and annotation, variant analysis (SNVs and InDels), genome comparison to reference strains, and taxonomic identity confirmation (ANI analysis) for strain characterization.

Quantifiable outcome

• rBSA is 20–100x more effective as a blocking agent than plasma-derived BSA, allowing dilution of 1:20 to 1:100 vs conventional BSA concentrations (~1 g/L)
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

14 partnerships are on record, tiered core and minor.

• CODANcoreStrategic or Co-development Partner · 1 January 2024SAVIA R&D project: CODAN, CNTA, and LEVPROT collaborating to create a new generation of healthy bakery products for active ageing. Levprot contributes brazzein and recombinant proteins. Total project budget €1,010,724.81; Levprot budget €352,022.36 (CDTI loan €229,096.30 + grant €55,429.74). Execution period 10/2025–10/2028.
• CNTA (Centro Nacional de Tecnología y Seguridad Alimentaria)coreStrategic or Co-development Partner · 1 January 2024SAVIA R&D project partner alongside CODAN and LEVPROT. CNTA contributes food technology and safety expertise. Project aims to develop healthy bakery products integrating functional ingredients including recombinant proteins.
• FATE (Food Applications of Technology and Engineering)minorGTM or Marketing Partner · 1 January 2024Foodtech industry association. Levprot exhibited alongside FATE at Food4Future Bilbao 2024 and 2025 events (Booth 1C301). Combined R&D and application expertise to present foodtech innovations and explore manufacturing partnership opportunities.
• Government of AragoncoreOthers · 1 January 2022Co-financing partner for multiple R&D projects in the pharmaceutical sector. Contributed €1,501,109.50 to Next-Generation Therapies project (€3,002,219 total), €783,505 to 5P Medicine Platform project (€1,567,010 total), and €139,415.50 to Next-Generation Therapies Phase 2.
• CDTI (Centro para el Desarrollo Tecnológico Industrial)coreOthers · 1 January 2022Spanish government agency providing R&D funding. Key grants include: CDTI-NEOTEC 2023 (€325,000 contribution), STABVAC4COV (€1,668,215.25), END-RAM (€248,361 grant). CDTI funding supports innovative biotech companies through various programs.
• Ministry of Science and Innovation (Spain)coreOthers · 1 January 2022Government body that granted Levprot the Innovative SME Seal (since June 2022). Supports Torres Quevedo Program (3 doctoral researcher grants), CDTI programs, and ICEX export initiatives. END-RAM and STABVAC4COV projects received Ministry support.
• Certest BioteccoreStrategic or Co-development Partner · 1 January 2021Consortium leader for multiple collaborative R&D projects involving Levprot: STABVAC4COV (thermostable mRNA vaccines against SARS-CoV-2 delta variant), Next-Generation Therapies (nanoencapsulated nucleic acids), 5P Medicine Platform (NGS-based personalized medicine), and END-RAM (RNA therapies and advanced diagnostics for antimicrobial resistance). Levprot develops enzymes of interest for these technologies.
• Universidad de ZaragozaminorStrategic or Co-development Partner · 1 January 2021Academic collaboration partner in the STABVAC4COV mRNA vaccine project, contributing scientific expertise alongside Certest Biotec, Levprot, Lev2050, 53biologics, and Innoup Pharma.
• Universidad de NavarraminorStrategic or Co-development Partner · 1 January 2021Academic collaboration partner in the STABVAC4COV mRNA vaccine project. Collaborates with Certest Biotec, Levprot, Lev2050, 53biologics (BDI), and Innoup Pharma.
• Lev2050minorStrategic or Co-development Partner · 1 January 2021Project partner in STABVAC4COV cooperative project led by Certest Biotec. Levprot and Lev2050 collaborate on development of enzymes for mRNA vaccine technology.
• 53biologics (BDI)minorStrategic or Co-development Partner · 1 January 2021Project partner in STABVAC4COV cooperative project led by Certest Biotec. Contributes to development of thermostable mRNA vaccine technology.
• Innoup PharmaminorStrategic or Co-development Partner · 1 January 2021Project partner in STABVAC4COV cooperative project led by Certest Biotec. Contributes pharmaceutical formulation expertise to the mRNA vaccine development consortium.
• ICEX (Instituto de Comercio Exterior)coreOthersSpanish export promotion agency supporting Levprot's international expansion through the ICEX-Next Export Initiation Program with ERDF co-financing. Enables Levprot's participation in international trade fairs via Spain Pavilions (MEDLAB Dubai, BIOJAPAN, AFTEA Singapore, ADLM Chicago).
• IDAE (Instituto para la Diversificación y Ahorro de la Energía)minorOthersSpanish energy agency. Supported installation of photovoltaic canopy with electric vehicle charging points at Levprot's Zaragoza facility through MOVES III program. Total investment €34,884.53; grant amount €7,205.10. Supported by Ministry for Ecological Transition and Demographic Challenge.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• The EVERY Company: Precision fermentation company producing animal-free proteins including egg and dairy alternatives. Comparable to Levprot's foodtech/nutraceutical positioning around Brazzein and recombinant functional proteins.
• Perfect Day: Precision fermentation producer of animal-free whey protein via microbial fermentation. Comparable emerging player in the alternative-protein space where Levprot's Brazzein and rBSA NutraGrade compete for foodtech mindshare.
• Codexis: Protein engineering company leveraging directed evolution to develop novel enzymes and biotherapeutics. Adjacent peer — competes with Levprot in enzyme development but differentiates via protein engineering rather than yeast chassis expression.

Direct peers

• InVitria: Producer of animal-free recombinant proteins (recombinant albumin, lactoferrin, transferrin) for cell culture and bioprocessing. Directly comparable to Levprot's cell culture supplement line and rBSA NutraGrade offering.
• Conagen: US-based precision fermentation CDMO producing ingredients via microbial fermentation for food, beauty, and pharma. Directly comparable to Levprot's CDMO/CDO service offering and recombinant protein portfolio.
• BRAIN Biotech: German precision fermentation company developing specialty enzymes and bioactive compounds via microbial expression. Directly comparable to Levprot's YEASTech® platform in technology approach and customer segments.
• Albumedix: Recombinant human albumin (Recombumin) supplier for cell culture, vaccines, and drug delivery. Closest direct comparable to Levprot's rBSA portfolio for cell culture and pharma-grade applications.

Broad incumbents

• Novonesis (Novozymes / Chr. Hansen): World's largest industrial enzyme manufacturer formed via merger of Novozymes and Chr. Hansen, with broad foodtech, health, and industrial enzyme portfolios. Competes with Levprot's enzyme catalog across multiple verticals as a broad incumbent.
• AB Enzymes: Specialty enzyme manufacturer (part of ABF Ingredients) producing enzymes for baking, brewing, dairy, and food processing. Broad incumbent competing with Levprot's enzyme catalog in industrial applications.
• Merck KGaA (Life Science / MilliporeSigma): Global life science supplier selling BSA, recombinant proteins, enzymes, and bioprocessing reagents across diagnostics, pharma, and academic segments. Broad incumbent against which Levprot's rBSA and enzyme catalog compete.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/levprot-bioscience

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about levprot